Jilin Aodong Pharmaceutical Group Co Ltd
SZSE:000623
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (0.6), the stock would be worth ¥16.71 (11% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.7 | ¥18.87 |
0%
|
| 3-Year Average | 0.6 | ¥16.71 |
-11%
|
| 5-Year Average | 0.6 | ¥17.15 |
-9%
|
| Industry Average | 2 | ¥55.41 |
+194%
|
| Country Average | 1.9 | ¥52.24 |
+177%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SZSE:000623
|
22.6B CNY | 0.7 | 8.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 8.9 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 3.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 2.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 3.7 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 2.9 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 2.6 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 56 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 2.7 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 1 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | -9.1 | 4 516.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.9 |
| 70th Percentile | 3.4 |
| Max | 1 129 391.6 |
Other Multiples
Jilin Aodong Pharmaceutical Group Co Ltd
Glance View
Jilin Aodong Pharmaceutical Group Co Ltd., nestled in the northeastern province of Jilin in China, has steadily crafted its narrative as a pivotal player in the pharmaceutical industry, blending traditional Chinese medicine with modern pharmaceuticals. The company began its journey focusing on the rich heritage of Chinese medicine, a reflection of the deep cultural roots in its origins, and gradually expanded into the realm of western pharmaceuticals. This dual approach has enabled Jilin Aodong to strategically position itself, catering to diverse market needs both domestically and internationally. By leveraging its expertise in research and development, the company has developed an array of products, including herbal medicine, chemical drugs, and biological pharmaceuticals, which are integral to its robust product portfolio. Driving its revenue engine is not just the sale of its diverse medicinal products, but also strategic investments and partnerships. Jilin Aodong's vertically integrated business model encompasses all aspects of pharmaceutical production, from sourcing raw materials to manufacturing and distribution, ensuring cost efficiency and quality control. Additionally, the company often engages in strategic alliances to amplify its market presence and innovation capabilities. By maintaining a balance between the time-tested efficacy of traditional medicine and the evolving demands of modern healthcare, Jilin Aodong establishes a unique market niche and secures a steady revenue stream, while continually seeking opportunities for expansion and innovation in the pharmaceutical landscape.